Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. by Hale, G, Rebello, P, Al Bakir, I, Bolam, E, Wiczling, P, Jusko, W, Vandemeulebroucke, E, Keymeulen, B, Mathieu, C, Ziegler, A, Chatenoud, L, Waldmann, H